Showing 3341-3350 of 4110 results for "".
- FDA Approves Stelara for Treatment of Adolescents with Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-stelara-for-treatment-of-adolescents-with-moderate-to-severe-plaque-psoriasis/2458010/The FDA approved an expanded indication for Janssen Biotech, Inc.'s Stelara (ustekinumab) for the treatment of adolescents (12 years of age or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Today's approval marks a significant mile
- FDA Approves Injection of Restylane Silk via Cannula for Lip Augmentationhttps://practicaldermatology.com/news/fda-approves-injection-of-restylane-silk-via-cannula-for-lip-augmentation/2458012/The FDA has approved the use of a small blunt tip cannula with Galderma's Restylane Silk for lip augmentation. Restylane Silk was the first FDA-approved hyaluronic acid (HA) dermal filler specifically designed for lip augmentation and the smoothing of wrinkles around the mouth in patients 21
- Biofrontera Appoints Jeffrey Holm as VP of Marketinghttps://practicaldermatology.com/news/biofrontera-appoints-jeffrey-holm-as-vp-of-marketing/2458013/Biofrontera AG, which specializes in the treatment of sun-induced skin cancer, has appointmented Jeffrey Holm as Vice President of Marketing, to further strengthen its US commercialization activities.
- Five ASDS Members Receive President's Awards at Annual Meetinghttps://practicaldermatology.com/news/five-asds-members-receive-presidents-awards-at-annual-meeting/2458024/Five members of the American Society for Dermatologic Surgery (ASDS) received President’s Awards for their contributions to the Society and dermatologic specialty at the 2017 ASDS Annual Meeting in Chicago. The 2017 recipients were Murad Alam, MD,
- Medicaid Patients May Receive Less Timely Melanoma Surgeryhttps://practicaldermatology.com/news/medicaid-patients-may-receive-less-timely-melanoma-surgery/2458028/Delays in melanoma surgery may vary by insurance type, according to research in JAMA Dermatology. While Medicaid patients had the highest likelihood of delays, significant pro
- ISHRS: Hair Restoration Surgery at All-Time Highhttps://practicaldermatology.com/news/ishrs-hair-restoration-surgery-at-all-time-high/2458029/Hair restoration is having a moment. The worldwide volume of surgical hair restoration procedures performed from 2014 to 2016 rose 60 percent, with 635,189 procedures performed worldwide in 2016, according to the latest’s statistics from the
- Penn Derm Awarded $8.6M to Study Home Versus In-Office Phototherapy Treatment for Psoriasishttps://practicaldermatology.com/news/penn-derm-awarded-86m-to-study-home-versus-in-office-phototherapy-treatment-for-psoriasis/2458030/A research team at the University of Pennsylvania will receive $8.6 million to study the effectiveness of home-based phototherapy treatments for psoriasis compared to treatments that require a visit to a doctor’s office three times a week. The Patien
- Study IDs Racial and Ethnic Disparities in Pediatric Eczema Treatmenthttps://practicaldermatology.com/news/study-ids-racial-and-ethnic-disparities-in-pediatric-eczema-treatment/2458033/White children in the US are more likely to see a doctor for treatment of eczema than black children, despite the fact that the disease is likely more severe among minorities. Research from the Perelman School of Medicine at the University of Pennsylvan
- Dermavant Sciences Appoints Vince Ippolito as President and COOhttps://practicaldermatology.com/news/dermavant-sciences-appoints-vince-ippolito-as-president-and-coo/2458034/Dermavant Sciences, a biopharmaceutical company focused on developing therapies for dermatologic conditions, appointed Vince Ippolito as President and Chief Operating Officer. "I am extremely pleased to welcome Vince Ippolito
- Novan Has Guidance Meeting with FDA on SB204https://practicaldermatology.com/news/novan-has-guidance-meeting-with-fda-on-sb204/2458040/Novan, Inc. is eyeing an additional pivotal trial for its investigational treatment for acne vulgaris, SB204. The company concluded a guidance meeting with the FDA regarding SB204 in which the agency advised that an additional pivotal trial should be conducted. Given the need for the ad